A detailed history of Vantage Consulting Group Inc transactions in Incyte Corp stock. As of the latest transaction made, Vantage Consulting Group Inc holds 3,958 shares of INCY stock, worth $226,912. This represents 0.33% of its overall portfolio holdings.

Number of Shares
3,958
Previous 4,280 7.52%
Holding current value
$226,912
Previous $268,000 16.04%
% of portfolio
0.33%
Previous 0.41%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $18,209 - $21,441
-322 Reduced 7.52%
3,958 $225,000
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $34,373 - $42,301
659 Added 18.2%
4,280 $268,000
Q3 2023

Nov 14, 2023

SELL
$57.77 - $65.93 $8,954 - $10,219
-155 Reduced 4.1%
3,621 $209,000
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $27,305 - $33,828
448 Added 13.46%
3,776 $235,000
Q1 2023

May 10, 2023

BUY
$70.23 - $86.01 $27,600 - $33,801
393 Added 13.39%
3,328 $240,000
Q4 2022

Feb 13, 2023

SELL
$67.18 - $84.11 $42,054 - $52,652
-626 Reduced 17.58%
2,935 $235,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $9,927 - $12,429
150 Added 4.4%
3,561 $237,000
Q2 2022

Aug 09, 2022

BUY
$66.18 - $83.18 $20,184 - $25,369
305 Added 9.82%
3,411 $259,000
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $57,635 - $69,586
-873 Reduced 21.94%
3,106 $247,000
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $34,520 - $40,389
545 Added 15.87%
3,979 $292,000
Q3 2021

Nov 10, 2021

BUY
$68.67 - $84.02 $46,420 - $56,797
676 Added 24.51%
3,434 $236,000
Q2 2021

Aug 11, 2021

BUY
$79.87 - $87.53 $220,281 - $241,407
2,758 New
2,758 $232,000
Q1 2021

May 14, 2021

SELL
$76.02 - $100.5 $68,189 - $90,148
-897 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$80.74 - $97.7 $72,423 - $87,636
897 New
897 $78,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $12.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Vantage Consulting Group Inc Portfolio

Follow Vantage Consulting Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.